Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corp    CVS

Delayed Quote. Delayed  - 10/21 10:00:33 pm
87.41 USD   +0.13%
10/21 CVS HEALTH : Pay goes live nationwide
10/20 CVS HEALTH : Safe Drug Disposal is Key to Preventing Abuse
10/20 CVS HEALTH : Announces 47 Metric Tons of Unwanted Medication Collect..
News SummaryMost relevantAll newsSector news 

Exclusive: Ernst, audit clients cut lobbying ties-records

share with twitter share with LinkedIn share with facebook
share via e-mail
05/04/2012 | 07:11am CEST

Ernst & Young's lobbying unit is no longer listed as a lobbyist for three major U.S. companies, all of whom were 2011 audit clients of the accounting giant. The deregistration follows questions raised by two U.S. senators in March about whether the dual relationships crossed auditor independence boundaries.

Documents filed last month with Congress showed that Washington Council Ernst & Young, the E&Y unit, was no longer registered as doing lobbying work for Amgen Inc (>> Amgen, Inc.), CVS Caremark Corp (>> CVS Caremark Corporation) and Verizon Communications Inc (>> Verizon Communications Inc.).

A lobbying-contract termination was also filed on March 31 for a fourth company, Nomura Holdings Inc (>> Nomura Holdings Inc.), which, according to securities filings, uses an E&Y affiliate for auditing services. E&Y had provided lobbying services to Nomura since June 2011, according papers on file with Congress.

Auditors that review corporations' books every year must follow rules limiting other ties with audit clients. The rules - meant to prevent auditors from getting too cozy with audit clients - were substantially beefed up a decade ago after a rash of accounting scandals at Enron Corp. and other companies.

An Ernst & Young spokesman declined to comment on the discontinued lobbying relationships. Officials with Nomura, Verizon and CVS declined to comment. Amgen officials could not immediately be reached for comment.

The chief accountant for the U.S. Securities and Exchange Commission, James Kroeker, speaking at a financial reporting conference at Baruch College in New York on Thursday, said SEC rules state an auditor should not act in an advocacy role for a company it audits and lobbying would be inconsistent with that.

Kroeker did not mention any audit firms by name.

He said: "If you think about lobbying in the traditional sense, you would say, 'wouldn't somebody that's lobbying be placing themselves in a position to be an advocate?'"

Asked whether the SEC was looking into E&Y's lobbying activities, an official in the agency's enforcement division declined to comment because its investigations are not public.

"We are aware of it and we are cognizant of what the rules are," said Howard Scheck, chief accountant of the SEC's division of enforcement, on the sidelines of Thursday's conference.

"If there's a violation that we find, we'll certainly do something about that," he said, without referring to E&Y.

Reuters reported in March that Washington Council Ernst & Young had been hired as a lobbyist for a number of E&Y's audit clients, prompting two lawmakers to demand closer scrutiny.

Democratic senators Carl Levin and Jack Reed both expressed concerns at the time and urged the SEC to look into the matter. On Thursday, Reed's office did not immediately respond to inquiries seeking comment. Levin's office declined to comment.

Verizon had a particularly long relationship with E&Y's lobbyists, who helped the telecommunications company with tax issues beginning in September 2001. The two other lobbying relationships were more recent, dating to February in the case of Amgen and September in the case of CVS Caremark. Both contracts were connected to corporate tax debates. The three U.S. terminations were all effective March 31 and Nomura's termination was filed the same day.

The E&Y spokesman referred Reuters to its earlier statement that Washington Council's work complied with independence rules.

The work was approved by clients' audit committees and it was limited to tax-related issues, E&Y spokesman Charles Perkins said when Reuters reported on the issue in March.

Washington Council did not solicit votes on legislation for E&Y audit clients, Perkins said.

The Public Company Accounting Oversight Board, the watchdog for U.S. auditors, is looking to shore up independence rules after finding numerous instances in which auditors did not dig deeply enough to challenge clients' financial numbers.

The SEC's Kroeker said he was encouraged to see the board tackling the subject.

"Independence is really the bedrock, the foundation of the value that's provided by a third-party audit," he said.

(Reporting by Dena Aubin and David Ingram; Additional reporting by Kim Dixon; Editing by Kevin Drawbaugh and Matt Driskill)

By David Ingram and Dena Aubin

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CVS HEALTH CORP
10/21 CVS HEALTH : Pay goes live nationwide
10/20 CVS HEALTH : SilverScript Insurance Company, a CVS Health Company, Introduces Ne..
10/20 WOMENHEART : The National Coalition for Women with Heart Disease Receives Commun..
10/20 CVS HEALTH : Safe Drug Disposal is Key to Preventing Abuse
10/20 CVS HEALTH : Announces 47 Metric Tons of Unwanted Medication Collected Through S..
10/20 CVS HEALTH : Dorchester Wealth Management Co buys $5,458,536 stake in CVS Health..
10/20 CVS HEALTH : Pharmacy Takes Pay Nationwide Following Successful Pilot
10/20 CVS HEALTH CORP : ex-dividend day
10/19 CVS HEALTH : Pharmacy to Help Patients Understand Health Insurance Options Durin..
10/19 CVS CAREMARK : How Competition Can Increase Access and Reduce Costs
More news
Sector news : Drug Retailers - NEC
10/21DJU.S. HOT STOCKS : Hot Stocks to Watch
10/20DJWalgreens, Rite Aid Push Back Merger Deadline -- Update
10/20 Walgreens sees Rite Aid deal closing in early 2017
10/20DJWALGREENS BOOTS ALLIANCE : Rite Aid Push Back Merger Deadline
10/10DJWALGREENS BOOTS ALLIANCE : Major Investor Sues Theranos
More sector news : Drug Retailers - NEC
News from SeekingAlpha
10/20 The Drug Battle Coming To A Neighborhood Near You
10/19 The Attractiveness Of CVS At $86 Instead Of $106
10/19 CVS : Garage Sale Bargain
10/19 CVS HEALTH CORPORATION : Attractively Valued And Set Up For Double Digit Returns
10/19 Buy CVS Health - Cramer's Lightning Round (10/18/16)
Financials ($)
Sales 2016 179 801 M
EBIT 2016 10 816 M
Net income 2016 5 730 M
Debt 2016 24 813 M
Yield 2016 1,88%
P/E ratio 2016 16,76
P/E ratio 2017 14,09
EV / Sales 2016 0,66x
EV / Sales 2017 0,60x
Capitalization 93 198 M
More Financials
Duration : Period :
CVS Health Corp Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Full-screen chart
Technical analysis trends CVS HEALTH CORP
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 108 $
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Stephen J. Gold Chief Information Officer & Executive Vice Preside
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORP-10.60%93 198
More Results